ES2155115T3 - Procedimiento para la preparacion de un derivado de tetrazol bajo dos formas cristalinas y nueva forma cristalina de este derivado. - Google Patents

Procedimiento para la preparacion de un derivado de tetrazol bajo dos formas cristalinas y nueva forma cristalina de este derivado.

Info

Publication number
ES2155115T3
ES2155115T3 ES95402322T ES95402322T ES2155115T3 ES 2155115 T3 ES2155115 T3 ES 2155115T3 ES 95402322 T ES95402322 T ES 95402322T ES 95402322 T ES95402322 T ES 95402322T ES 2155115 T3 ES2155115 T3 ES 2155115T3
Authority
ES
Spain
Prior art keywords
tetrazol
derivative
bifenil
ona
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95402322T
Other languages
English (en)
Inventor
Antoine Caron
Dominique Chantreux
Colette Bouloumie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2155115T3 publication Critical patent/ES2155115T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

SE DESCRIBE UN PROCESO PARA LA PREPARACION DE LA 2-N.BUTIL3[[2`TETRAZOL-5-IL)BIFENIL-4-IL]METIL]-1,3-DIAZASPIRO[4.4]NON-1ENO-4-ONA POR REACCION DEL NITRILO CORRESPONDIENTE CON UN AZOTURO ALCALINO Y EL CLORHIDRATO DE TRIETILAMINA, RECUPERANDO LA 2N.BUTIL-3[[2`TETRAZOL-5-IL)BIFENIL-4-IL]METIL]-1,3DIAZASPIRO[4.4]NON-1-ENO-4-ONA EN FORMA DE UNA DE SUS SALES ALCALINAS EN SOLUCION ACUOSA, POR NEUTRALIZACION DE DICHA SAL ALCALINA Y CRISTALIZACION DE LA 2-N.BUTIL-3[[2`TETRAZOL-5IL)BIFENIL-4-IL]METIL]-1,3-DIAZASPIRO[4.4]NON-1-ENO-4-ONA ASI PRECIPITADA BIEN EN UN SOLVENTE QUE CONTIENE MENOS DE 10% DE AGUA, BIEN EN UN SOLVENTE QUE CONTIENE MAS DE 10% DE AGUA PARA OBTENER DOS FORMAS CRISTALINAS DIFERENTES. APLICACION: OBTENCION DE UNA NUEVA FORMA CRISTALINA DE LA 2-N.BUTIL-3[[2`TETRAZOL-5IL)BIFENIL-4-IL]METIL]-1,3-DIAZASPIRO[4.4]NON-1-ENO-4-ONA Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN.
ES95402322T 1994-10-19 1995-10-18 Procedimiento para la preparacion de un derivado de tetrazol bajo dos formas cristalinas y nueva forma cristalina de este derivado. Expired - Lifetime ES2155115T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9412459A FR2725987B1 (fr) 1994-10-19 1994-10-19 Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Publications (1)

Publication Number Publication Date
ES2155115T3 true ES2155115T3 (es) 2001-05-01

Family

ID=9467986

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95402322T Expired - Lifetime ES2155115T3 (es) 1994-10-19 1995-10-18 Procedimiento para la preparacion de un derivado de tetrazol bajo dos formas cristalinas y nueva forma cristalina de este derivado.

Country Status (26)

Country Link
US (1) US5629331A (es)
EP (1) EP0708103B1 (es)
JP (1) JP3366786B2 (es)
KR (1) KR100251222B1 (es)
CN (1) CN1061656C (es)
AT (1) ATE198478T1 (es)
AU (1) AU698041B2 (es)
CA (1) CA2160725C (es)
CY (1) CY2277B1 (es)
CZ (2) CZ288629B6 (es)
DE (1) DE69519788T2 (es)
DK (1) DK0708103T3 (es)
ES (1) ES2155115T3 (es)
FI (1) FI114156B (es)
FR (1) FR2725987B1 (es)
GR (1) GR3035503T3 (es)
HU (1) HU226461B1 (es)
IL (1) IL115688A (es)
NO (1) NO307516B1 (es)
NZ (1) NZ280293A (es)
PL (1) PL184193B1 (es)
PT (1) PT708103E (es)
RU (1) RU2144536C1 (es)
SI (1) SI0708103T1 (es)
TW (1) TW357147B (es)
ZA (1) ZA958850B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
PT1094816E (pt) 1998-07-06 2009-03-10 Bristol Myers Squibb Co Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina
BR0112665A (pt) * 2000-07-19 2003-06-24 Novartis Ag Sais
US20050176793A1 (en) * 2001-12-10 2005-08-11 Reddy Reguri B. Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one
DE60308708T2 (de) * 2002-07-16 2007-08-23 Teva Pharmaceutical Industries Ltd. Neue synthese von irbesartan
WO2004065383A2 (en) * 2003-01-16 2004-08-05 Teva Pharmaceutical Industries Ltd. Novel synthesis of irbesartan
DE602004015071D1 (de) * 2003-02-05 2008-08-28 Teva Pharma Synthese von 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro-4,4 -nonen-4-on
AU2003242984A1 (en) * 2003-04-07 2004-11-01 Hetero Drugs Limited A novel crystalline form of irbesartan
PL379420A1 (pl) * 2003-07-31 2006-09-04 Nicox S.A. Pochodne blokerów receptora angiotensyny II
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005051943A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Processes for the preparation of highly pure irbesartan
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006001026A1 (en) * 2004-06-23 2006-01-05 Hetero Drugs Limited Irbesartan polymorphs
SI21849A (sl) * 2004-07-29 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Priprava hidrokloridnih soli tetrazolskega derivata
TWI346108B (en) * 2004-08-23 2011-08-01 Bristol Myers Squibb Co A method for preparing irbesartan and intermediates thereof
GB2419592A (en) * 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
WO2006050923A1 (en) * 2004-11-11 2006-05-18 Lek Pharmaceuticals D.D. Polymorph form of irbesartan
ES2259909B1 (es) * 2005-02-28 2007-06-16 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de su intermedio de sintesis.
WO2007013101A1 (en) * 2005-07-27 2007-02-01 Jubilant Organosys Limited PROCESS FOR PRODUCING 2-(N-BUTYL)-3-[[2'-(TETRAZOL-5-YL)BIPHENYL- 4-YL]METHYL]-l,3-DIAZASPIRO[4.4] NON-1-EN-4-ONE
PL1806130T3 (pl) 2006-01-09 2010-08-31 Krka D D Novo Mesto Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan
WO2008041957A1 (en) * 2006-10-03 2008-04-10 Ulkar Kimya Sanayi Ve Ticaret As Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one
EP1918288A1 (en) 2006-11-02 2008-05-07 Cadila Pharmaceuticals Limited A novel and improved process for the preparation of Irbesartan, an angiotensin-II receptor antagonist for the treatment of hypertension
PT2065035E (pt) 2007-11-28 2010-10-04 Lesvi Laboratorios Sl Formulações farmacêuticas contendo irbesartan
EP2215083A2 (en) * 2007-12-07 2010-08-11 Hetero Drugs Limited Process for pure irbesartan
KR101009383B1 (ko) * 2008-04-30 2011-01-19 켐젠주식회사 고순도의2-부틸-3-[[2'-(1에이취-테트라졸-5-일)[1,1'-비페닐]-4-일]메틸]-1,3-디아자스피로[4.4]논-1-엔-4-온 화합물의제조방법
EP2417110B1 (en) * 2009-04-08 2014-05-07 CTX Life Sciences Pvt. Ltd. A one pot process for preparing 2-butyl-3-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4]non-1-en-4-one (irbesartan)
AR078107A1 (es) * 2009-08-31 2011-10-12 Sanofi Aventis Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca
US8080670B2 (en) 2010-05-04 2011-12-20 Divi's Laboratories, Ltd. Process for the preparation of irbesartan
FR2977253B1 (fr) 2011-06-30 2013-08-09 Centre Nat Rech Scient Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
EP4408836A1 (en) 2021-10-01 2024-08-07 Sanofi Process for preparing sartan active compounds having a tetrazole ring

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2697919B2 (ja) * 1989-09-29 1998-01-19 キヤノン株式会社 信号内挿回路及び該回路を備えた変位測定装置
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5104891A (en) * 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
PT97078B (pt) * 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
NZ280293A (en) 1997-10-24
FR2725987A1 (fr) 1996-04-26
CZ271095A3 (en) 1996-05-15
SI0708103T1 (en) 2001-04-30
CZ288624B6 (cs) 2001-08-15
US5629331A (en) 1997-05-13
NO954154L (no) 1996-04-22
CN1061656C (zh) 2001-02-07
CY2277B1 (en) 2003-07-04
HUT73179A (en) 1996-06-28
NO307516B1 (no) 2000-04-17
FI114156B (fi) 2004-08-31
ATE198478T1 (de) 2001-01-15
PL184193B1 (pl) 2002-09-30
CZ288629B6 (cs) 2001-08-15
EP0708103B1 (fr) 2001-01-03
HU9503016D0 (en) 1995-12-28
EP0708103A1 (fr) 1996-04-24
FI954992L (fi) 1996-04-20
GR3035503T3 (en) 2001-06-29
AU698041B2 (en) 1998-10-22
IL115688A (en) 1999-09-22
RU2144536C1 (ru) 2000-01-20
JPH08208642A (ja) 1996-08-13
PT708103E (pt) 2001-06-29
CA2160725A1 (en) 1996-04-20
KR100251222B1 (ko) 2000-05-01
HU226461B1 (en) 2008-12-29
NO954154D0 (no) 1995-10-18
IL115688A0 (en) 1996-01-19
CA2160725C (en) 2001-12-18
FI954992A0 (fi) 1995-10-19
CN1128261A (zh) 1996-08-07
DE69519788D1 (de) 2001-02-08
HK1005135A1 (en) 1998-12-24
JP3366786B2 (ja) 2003-01-14
PL311012A1 (en) 1996-04-29
ZA958850B (en) 1996-05-27
DE69519788T2 (de) 2001-08-30
KR960014122A (ko) 1996-05-22
DK0708103T3 (da) 2001-04-23
FR2725987B1 (fr) 1997-01-10
TW357147B (en) 1999-05-01
AU3433595A (en) 1996-05-02

Similar Documents

Publication Publication Date Title
TW357147B (en) Process for the preparation of a tetrazole derivative in two crystalline forms and novel crystalline form of said derivative
NO974163D0 (no) Ester av 5-aminolevulinsyre som fotosensibiliserings-middel i fotokjemoterapi
DE60315709D1 (de) Festphasenherstellung von 18f-markierten aminosäuren
BG101308A (bg) Повърхностноактивни състави
AR059763A2 (es) Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir
DK1177176T3 (da) Triarylsyrederivater som PPAR-receptorligander
HUP9802517A2 (hu) Foszfonsavval helyettesített benzazepinon-N-ecetsav-származékok, eljárás ezek előállítására és az e vegyületeket tartalmazó gyógyászati készítmények
RU92016217A (ru) Двойные ингибиторы no синтазы и циклооксигеназы, способ их получения и фармацевтическая композиция на их основе
AR026087A1 (es) Aminoacidos biciclicos como agentes farmaceuticos.
TNSN98216A1 (fr) Derives d'acide hydrauxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
ATE306917T1 (de) Pharmazeutische zusammensetzung mit 2-(4- isobutylphenyl) propionsäure
GT200500257AA (es) Procedimiento para producir derivados de amina opticamente activos
BR0213760A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
BR0307782A (pt) Compostos azabiciclo para o tratamento de doença
ES8303429A1 (es) Procedimiento para la obtencion de compuestos del acido 7b-amino-tiadiazolilacetilamino-3-amoniometil-3-cefem-4-car-boxilico
ES2103325T3 (es) Sales solubles de ibuprofen y naproxen con n-(2-hidroxietil) pirrolidina y composiciones farmaceuticas que contienen dichas sales.
NZ326367A (en) Use of glutaprotamin like surfactants for cleaning and disinfecting sensitive medical instruments
DK0472501T3 (da) Codeinsalt af en substitueret carboxylsyre, fremgangsmåde til dets fremstilling, dets anvendelse samt farmaceutiske præparater
SE9903831D0 (sv) Formulation of substituted benzimidazoles
BR0206730A (pt) Processo para preparar uma composição de valproato de sódio não-higroscópica, composição farmacêutica não-higroscópia e seu uso
ITMI911853A1 (it) Sale del diclofenac, metodo di preparazione e composizioni farmaceutiche che lo contengono.
ES2163528T3 (es) Una solucion acuosa para infusion, estable al almacenamiento, que contiene un inhibidor de trombina.
BRPI0408270A (pt) composição farmacêutica compreendendo ácido 5-metil-2-(2'cloro-6'-fluoroanilino)fenilacético
DK390384D0 (da) Midler med antimikrobiel virkning indeholdende derivater af benzoesyr og deres anvendelse som desinficerende laegemidler eller konserveingsmidler
ES8303376A1 (es) "procedimiento para la preparacion de nuevas 2(3h)-benzotiazolonas".

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 708103

Country of ref document: ES